2025-07-22 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc (TDOC) based on the provided data, formatted for a concise and informative report.

**Teladoc Health Inc (TDOC) Analysis**

Teladoc Health Inc is a telehealth and virtual healthcare company.

**1. Performance vs. S&P 500 (VOO)**

*   **TDOC Cumulative Return:** -64.35%
*   **VOO Cumulative Return:** 98.15%
*   **Absolute Divergence:** -162.5
*   **Relative Divergence:** 0.0 (near the lowest end of its historical range relative to VOO)

**Analysis:** TDOC has significantly underperformed the S&P 500. The large negative divergence indicates substantial relative weakness. The relative divergence being at the lowest end suggests this underperformance is near its historical worst compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| :----------- | :------ | :------ | :------ | :---- | :------- |
| 2015-2017  | 76.0%   | 60.6% | 50.0%   | -0.0  | 6.1      |
| 2016-2018  | 128.0%  | 59.3% | 110.0%  | -0.0  | 8.7      |
| 2017-2019  | 176.0%  | 59.3% | 147.0%  | 0.4   | 14.7     |
| 2018-2020  | 237.0%  | 64.0% | 217.0%  | 0.1   | 35.1     |
| 2019-2021  | -83.0%  | 64.0% | -132.0% | 0.1   | 16.1     |
| 2020-2022  | -295.0% | 81.3% | -297.0% | 0.0   | 4.2      |
| 2021-2023  | -488.0% | 81.3% | -506.0% | -0.6  | 3.8      |
| 2022-2024  | -111.0% | 81.3% | -137.0% | -0.8  | 1.6      |
| 2023-2025  | -35.0%  | 72.9% | -84.0%  | -0.8  | 1.5      |

**Analysis:**

*   **CAGR:** The CAGR (Compound Annual Growth Rate) shows strong growth in the earlier periods (2015-2020), followed by significant negative growth in recent years.
*   **MDD:** The Maximum Drawdown (MDD) indicates substantial risk, with drawdowns exceeding 59% in all periods and as high as 81.3% in recent years.
*   **Alpha:** Alpha is extremely high in the earlier years but has become very negative, indicating substantial underperformance relative to the market.
*   **Beta:** Beta values are generally low, indicating the stock has a weak correlation with the market. The negative betas in recent years suggest an inverse correlation.
*   **Market Cap:** Decreasing market capitalization could reflect a decrease in investor confidence.

**2. Recent Stock Price Movement**

*   **Current Price:** 8.33
*   **Previous Close:** 8.05
*   **Change:** 3.48%
*   **5-day Moving Average:** 8.042
*   **20-day Moving Average:** 8.243
*   **60-day Moving Average:** 7.4983

**Analysis:** The price is currently above the 5-day and 20-day moving averages, suggesting short-term upward momentum. The price is above the 60-day moving average, indicating a possible longer-term recovery, but this needs to be confirmed by further price action. The 3.48% change from the previous close is a notable jump, suggesting a potential short-term buying interest or reaction to recent news.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3383 (Low Risk)
*   **RSI:** 43.31 (Neutral)
*   **PPO:** -0.7986 (Bearish, but approaching oversold)
*   **Hybrid Signal:** cash_69%_Sell 1.0% of holdings
*   **Delta_Previous_Relative_Divergence:** -0.1 (Short-term decline)
*   **Expected Return:** -9698.9% (Significant underperformance relative to the S&P 500 over a 2+ year investment horizon)

**Analysis:**

*   **MRI:** The low MRI suggests a generally stable market environment.
*   **RSI:** An RSI of 43.31 is neutral, neither overbought nor oversold.
*   **PPO:** The negative PPO indicates that the stock is in a downtrend, but it is approaching oversold conditions, which could lead to a potential bounce.
*   **Hybrid Signal:** The signal suggests a cautious approach, recommending a high cash position and a slight reduction in holdings.
*   **Delta Relative Divergence:** Indicates the short-term underperformance relative to the index.
*   **Expected Return:** The extremely negative expected return suggests that analysts anticipate the stock will continue to significantly underperform the S&P 500 over the long term.

**4. Recent News & Significant Events:**

*   **[2025-07-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-21]:** Analysts discussing performance and outlook.
*   **[2025-07-20]:** Stock volatility due to recent news, earnings, or executive actions.
*   **[2025-07-19]:** Market experts highlighting risks and opportunities.

**Analysis:** The news indicates that Teladoc is experiencing significant activity and scrutiny, with both potential risks and opportunities being highlighted. Volatility is present, and investors are advised to monitor news and company announcements closely.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
| :--------- | :---- | :---------- |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2024-04-26 | -0.49 | 0.65 B$   |
| 2025-05-01 | -0.49 | 0.65 B$   |

**Analysis:** The company has consistently reported negative EPS (Earnings Per Share) in recent quarters. Revenue has remained relatively stable, fluctuating between $0.63B and $0.65B. The large negative EPS on 2024-08-01 is a significant concern.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :------------ |
| 2025-03-31   | $0.63B    | 68.73%        |
| 2024-12-31   | $0.64B    | 70.50%        |
| 2024-09-30   | $0.64B    | 71.94%        |
| 2024-06-30   | $0.64B    | 70.73%        |
| 2024-03-31   | $0.65B    | 69.89%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
| :----------- | :-------- | :------- |
| 2025-03-31   | $1.43B    | -6.52%   |
| 2024-12-31   | $1.49B    | -3.25%   |
| 2024-09-30   | $1.51B    | -2.21%   |
| 2024-06-30   | $1.50B    | -55.77%  |
| 2024-03-31   | $2.29B    | -3.58%   |

**Analysis:**

*   **Revenue and Profitability:** The revenue has been relatively stable over the past few quarters. However, the profit margin, while seemingly high, doesn't translate to actual profit due to other expenses.
*   **Capital and Profitability:** Equity has decreased significantly, and the negative ROE (Return on Equity) indicates that the company is not generating profits from its equity. The large negative ROE in 2024-06-30 is particularly concerning.

**7. Overall Analysis:**

Teladoc Health Inc (TDOC) is currently facing significant challenges. The company has a history of underperforming the S&P 500, which is reflected in negative cumulative returns, substantial negative alpha, and a large negative expected return. While revenue has been stable, the company struggles with profitability, as evidenced by negative EPS and ROE.

The recent news suggests volatility and scrutiny, with potential risks and opportunities. The technical indicators provide mixed signals: a recent price increase is countered by a bearish PPO. The hybrid signal recommends a cautious approach.

**Recommendation:** Based on the provided data, a cautious approach to TDOC is warranted. Investors should closely monitor the company's earnings, news, and announcements. Further improvements in profitability and a reversal of the underperformance trend are needed before a more positive outlook can be considered. Given the negative expected return, long-term investment is particularly risky at this time.
